With their concept for the PDE-5-inhibitor Levitra® and its new orodispersible formulation (Levitra® ODT), the FH Healthcare team was able to convince Bayer Healthcare Pharmaceuticals in a pitch. Besides the development of material for global and local media relations, the work is focused on online communication.
After the successful start of working together with Levitra® ODT Bayer Healthcare Pharmaceuticals consigned the healthcare specialists from Frankfurt additionally with the PR budget for the area of Andrology, which embraces the testosterone portfolio of Bayer Healthcare. “We are very proud that we were able to expand our work with such an important client”, Dr. Stephan Kühne, Senior Vice President of Fleishman-Hillard and leader of the Healthcare Team, reports happily. Besides the new budgets, Fleishman-Hillard is in charge of the area of animal health of Bayer Vital GmbH.
For more information, please contact:
Dr. Stephan Kühne
Tel.: +49-69-40 57 02 – 357